Roundhill GLP-1 & Weight Loss ETF (OZEM)
| Assets | $56.72M |
| Expense Ratio | 0.59% |
| PE Ratio | 16.12 |
| Shares Out | 1.67M |
| Dividend (ttm) | $0.41 |
| Dividend Yield | 1.21% |
| Ex-Dividend Date | Dec 30, 2025 |
| Payout Ratio | 18.48% |
| 1-Year Return | +30.91% |
| Volume | 14,562 |
| Open | 33.62 |
| Previous Close | 33.42 |
| Day's Range | 33.61 - 33.89 |
| 52-Week Low | 20.01 |
| 52-Week High | 37.15 |
| Beta | n/a |
| Holdings | 25 |
| Inception Date | May 21, 2024 |
About OZEM
Fund Home PageThe Roundhill GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies from around the world involved in pharmaceutical drugs and supplements used for weight management. OZEM was launched on May 21, 2024 and is issued by Roundhill.
Top 10 Holdings
66.17% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 16.82% |
| Novo Nordisk A/S | NVO | 12.23% |
| Pfizer Inc. | PFE | 6.80% |
| Viking Therapeutics, Inc. | VKTX | 5.02% |
| Innovent Biologics, Inc. | 1801 | 4.68% |
| Roche Holding AG | ROG | 4.36% |
| Zealand Pharma A/S | ZEAL.DC | 4.15% |
| Hanmi Pharm. Co., Ltd. | 128940 | 4.09% |
| Ascletis Pharma Inc. | 1672 | 4.05% |
| Amgen Inc. | AMGN | 3.97% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 30, 2025 | $0.40991 | Dec 31, 2025 |
| Dec 30, 2024 | $0.05307 | Dec 31, 2024 |
News
OZEM Vs. THNR: Which Is The Better ETF In The GLP-1 And Weight Loss Space?
I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo Nordisk and ...
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This ...
Mag7, AI and GLP-1: Roundhill CEO on the hottest ETFs to watch
Dave Mazza, Roundhill Investments CEO, joins CNBC's Bob Pisani on “Halftime Report's” “ETF Edge” segment to discuss the firms' three ETFs following the Mag7, AI and GLP-1 themes.
Why Investors Haven't Feasted on Two New Weight-Loss ETFs
Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.
OZEM: Investing in the Weight Loss Craze
Roundhill Investments launched its GLP-1 and Weight Loss ETF (OZEM) on May 21st. Dave Mazza discusses investing in the weight loss craze.
This new weight loss drug ETF bets big on two of the industry's leading players
While Novo Nordisk and Eli Lilly have soared in the past year, Roundhill Investments sees bigger gains ahead for the GLP-1 drugmakers.
New funds jump on weight loss trade
Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)
OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK , May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF spon...
Roundhill to launch active weight loss ETF
Dave Mazza, Roundhill Investments CEO, sits down with CNBC's Bob Pisani to discuss the firm's new weight loss ETF (OZEM). They dig into the ETF's holdings, why it's actively managed and more.